Claims for Patent: 8,071,613
✉ Email this page to a colleague
Summary for Patent: 8,071,613
| Title: | Anti-constipation composition |
| Abstract: | An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in a ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): ##STR00001## where X.sub.1 and X.sub.2 are preferably both fluorine atoms. The composition can be used to treat constipation without substantive side-effects, such as stomachache. |
| Inventor(s): | Ueno; Ryuji (Potomac, MD) |
| Assignee: | Sucampo AG (Zurich, CH) |
| Application Number: | 11/142,251 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,071,613 |
| Patent Claims: |
1. A method for relieving constipation in a constipated patient or cleansing the bowel of a patient, comprising administering to said patient a therapeutically effective
amount of a composition comprising the bi-cyclic and mono-cyclic tautomers of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1, wherein the ratio of the bi-cyclic to mono-cyclic tautomer is at least 1:1.
2. The method according to claim 1, wherein the ratio of bi-cyclic to mono-cyclic tautomer is at least 20:1. 3. The method according to claim 1, wherein the ratio of bi-cyclic to mono-cyclic tautomer is about 96:4. 4. A method for relieving constipation in a constipated patient or cleansing the bowel of a patient, comprising administering to said patient a therapeutically effective amount of a composition comprising the bi-cyclic and mono-cyclic tautomers of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1,and at least one medium fatty acid triglyceride, wherein the ratio of the bi-cyclic to mono-cyclic tautomer is at least 1:1. 5. The method according to claim 4, wherein said medium chain fatty acid triglyceride is a triglyceride of fatty acid having 6-14 carbon atoms. 6. The method according to claim 4, wherein the triglyceride is present in an amount of 1-1,000,000 parts by weight based on one part by weight of the bi-cyclic structure. 7. The method according to claim 4, wherein the triglyceride is present in an amount of 5-500,000 parts by weight based on one part by weight of the bi-cyclic structure. 8. The method according to claim 4, wherein the triglyceride is present in an amount of 10-200,000 parts by weight based on one part by weight of the bi-cyclic structure. 9. The method according to claim 4, wherein said triglyceride is caprylic acid triglyceride and/or capric acid triglyceride. 10. The method according to claim 4, wherein the ratio of bi-cyclic to mono-cyclic tautomer is at least 20:1. 11. The method according to claim 4, wherein the ratio of bi-cyclic to mono-cyclic tautomer is about 96:4. 12. The method according to claim 1, wherein the composition is free of water. 13. The method according to claim 4, wherein the composition is free of water. 14. A method for treating constipation in a constipated patient or cleansing the bowel of a patient, comprising administering to said patient a therapeutically effective amount of a composition comprising the bi-cyclic and mono-cyclic tautomers of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1, wherein the ratio of the bi-cyclic to mono-cyclic tautomer is at least 1:1. 15. The method according to claim 14, wherein the ratio of bi-cyclic to mono-cyclic tautomer is at least 20:1. 16. The method according to claim 14, wherein the ratio of bi-cyclic to mono-cyclic tautomer is about 96:4. 17. The method according to claim 14, wherein the tautomers are present in the absence of water in the composition. 18. A method for treating constipation in a constipated patient or cleansing the bowel of a patient, comprising administering to said patient a therapeutically effective amount of a composition comprising the bi-cyclic and mono-cyclic tautomers of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1, and at least one medium fatty acid triglyceride, wherein the ratio of the bi-cyclic to mono-cyclic tautomer is at least 1:1. 19. The method according to claim 18, wherein said medium chain fatty acid triglyceride is a triglyceride of a fatty acid having 6-14 carbon atoms. 20. The method according to claim 18, wherein the triglyceride is present in an amount of 1-1,000,000 parts by weight based on one part by weight of the bi-cyclic structure. 21. The method according to claim 18, wherein the triglyceride is present in an amount of 5-500,000 parts by weight based on one part by weight of the bi-cyclic structure. 22. The method according to claim 18, wherein the triglyceride is present in an amount of 10-200,000 parts by weight based on one part by weight of the bi-cyclic structure. 23. The method according to claim 18, wherein said triglyceride is caprylic acid triglyceride and/or capric acid triglyceride. 24. The method according to claim 18, wherein the ration of bi-cyclic to mono-cyclic tautomer is at least 20:1. 25. The method according to claim 18, wherein the ratio of bi-cyclic to mono-cyclic tautomer is about 96:4. 26. The method according to claim 18, wherein the tautomers are present in the absence of water in the composition. |
